FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

SILVER SPRING, Md., June 29, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5…